An Overview of Performance Enhancing Drugs (PED’S) in Sports and WADA
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
(19) United States (12) Patent Application Publication (10) Pub
US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist. -
WO 2013/142184 Al 26 September 2013 (26.09.2013) P O P C T
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2013/142184 Al 26 September 2013 (26.09.2013) P O P C T (51) International Patent Classification: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, A61K 33/16 (2006.01) A61K 31/7048 (2006.01) HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, A61K 33/14 (2006.01) A61K 31/70 (2006.01) KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, A61K 33/18 (2006.01) A61K 31/4196 (2006.01) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, (21) International Application Number: RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, PCT/US20 13/030788 TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, (22) International Filing Date: ZM, ZW. 13 March 2013 (13.03.2013) (84) Designated States (unless otherwise indicated, for every (25) Filing Language: English kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, (26) Publication Language: English UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (30) Priority Data: TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, 61/612,689 19 March 2012 (19.03.2012) US EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (71) Applicant: YALE UNIVERSITY [US/US]; Two Whitney TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, Avenue, New Haven, CT 065 10 (US). -
Les Antidépresseurs De La Performance
Annales de Toxicologie Analytique, vol. XII, n° 1, 2000 Les antidépresseurs de la performance Performance antidepressant drugs Jean-Pierre GOULLÉ*, Christian LACROIX Laboratoire de Pharmacocinétique et de Toxicologie Clinique, Groupe Hospitalier BP 24 - 76083 LE HAVRE Cedex - Tel : 02 32 73 32 18 - Fax : 02 32 73 32 38 * Auteur à qui adresser la correspondance : Docteur Jean-Pierre GOULLÉ, Laboratoire de Pharmacocinétique et de Toxicologie Clinique, Groupe Hospitalier, Jacques Monod - BP 24 - 76083 LE HAVRE Tel : 02 32 73 32 23 - Fax : 02 32 73 32 38 (Reçu le 17 décembre 1999 ; accepté le 15 janvier 2000) RÉSUMÉ SUMMARY En France, au cours de la période 1991-1997, alors que la Whereas in France the sale of psychotropic medication vente des médicaments psychotropes a augmenté de 7 %, le increased 7 % in the period between 1991 and 1997, the marché des antidépresseurs s'est littéralement envolé avec antidepressant drugs market literally exploded with a pro• une progression de plus de 40 %. Cette consommation, 2 à 3 gression of 40 %. This consumption 2 to 3 times greater than fois plus importante que celle de nos voisins européens, est that of our European neighbours created an abuse which génératrice d'abus conduisant à une accoutumance, à une lead to habituation, to an addiction, and even to drug abuse. assuétude, voire à une véritable conduite toxicophile. Les Antidepressant drugs (AD) pertain to the substances which antidépresseurs (AD) font partie des substances qui sont uti• are used by man to improve its performance due to its phar• lisées par l'homme pour améliorer sa performance, en rai• macological effects. -
Baseball Statistics in the Steroids Era
BASEBALL STATISTICS IN THE STEROIDS ERA _________________________ By John Dechant _________________________ A THESIS Submitted to the faculty of the Graduate School of the Creighton University in Partial Fulfillment of the Requirements for the degree of Master of the Arts in the Department of Liberal Studies. _________________________ OMAHA, NEBRASKA JUNE 27, 2008 iii Abstract This thesis examines the presence of steroids and performance enhancing substances in Major League Baseball from approximately 1988 to 2008. This period, informally known as the “steroids era,” has been the source of great controversy in recent years as more and more information on the matter has been disclosed to the public. In particular, this discussion focuses on the records and statistics of this era. In addition to the players who achieved these statistics, these numbers should be under great scrutiny as their validity is questioned. CONTENTS PREFACE………………………………………………………………………………iv INTRODUCTION……………………………………………………………………….1 Chapter ONE HISTORICAL PATTERNS OF STEROID USE IN BASEBALL………5 The Nature of Performance Enhancing Substances………………5 Early Signs of Steroid Use in Major League Baseball…………....8 Early Major League Baseball Steroid Policy…………………….12 Contemporary Steroid Use in Major League Baseball and the Evolution of Testing Policy……………………………..14 Congressional Intervention and the Mitchell Report…………….23 TWO ETHICAL CONSIDERATIONS OF STEROIDS IN BASEBALL……32 The Prohibition Debate………………………………………….32 Records and Statistics……………………………………………46 THREE *ASTERISKS AND DISTINGUISHING MARKS……………………..54 Problems of the Steroids Era…......................................................54 Precedents………………………………………………………..60 Asterisk…………………………………………………………..62 Era Divide………………………………………………………..65 Status Quo………………………………………………………..66 Assessment……………………………………………………….67 CONCLUSION…………………………………………………………………………..70 BIBLIOGRAPHY………………………………………………………………………..71 iv Preface My opinion of steroids and performance enhancing substances in baseball changed on February 13, 2008. -
NFLIS-Drug Selected Substance List
2017-2020 NFLIS-Drug Substance List (Sorted by Date) Date Added NFLIS Substance Name Synonyms Chemical Name Structure InChI Formula to NFLIS- Drug InChI=1S/C16H20BrN/ c17-14-1-3-15(4-2-14)18-16-12-6-10-5-11 Bromantane ladasten N-(4-bromophenyl)adamantan-2-amine C16H20BrN 12/7/20 (8-12)9-13(16)7-10/h1-4,10-13,16,18H, 5-9H2 InChI=1S/C21H29FN2O3/ c1-4-27-21(26)19(15(2)3)23-20(25)17-14- ethyl 2-(1-(5-fluoropentyl)-1H-indole-3-carboxamido)-3- 5F-EMB-PICA EMB-2201; 5-fluoro-EMB-PICA 24(13-9-5-8-12-22)18-11-7-6-10-16(17)18 C21H29FN2O3 11/12/20 methylbutanoate /h6-7,10-11,14-15,19H, 4-5,8-9,12-13H2,1-3H3,(H,23,25) InChI=1S/C20H27FN2O3/ c1-20(2,3)17(19(25)26-4)22-18(24)15-13- methyl 2-(1-(4-fluorobutyl)-1H-indole-3- 4F-MDMB-BUTICA 4-fluoro-MDMB-BUTICA; 4F-MDMB-BICA 23(12-8-7-11-21)16-10-6-5-9-14(15)16/ C20H27FN2O3 10/23/20 carboxamido)-3,3-dimethylbutanoate h5-6,9-10,13,17H,7-8,11-12H2,1-4H3,(H, 22,24) InChI=1S/C10H14BrNO2/ 4-methoxy-6-[(1E)-2-phenylethenyl]-5,6-dihydro-2H- 2Br-4,5-Dimethoxyphenethylamine 2-bromo-4,5-dimethoxyphenethylamine c1-13-9-5-7(3-4-12)8(11)6-10(9)14-2/ C10H14BrNO2 10/2/20 pyran-2-one h5-6H,3-4,12H2,1-2H3 InChI=1S/C16H22FNO/ 4-fluoro-3-methyl-alpha-PVP; 4F-3-methyl-alpha- c1-3-6-15(18-9-4-5-10-18)16(19)13-7-8-1 4F-3-Methyl-alpha-PVP 4-fluoro-3-methyl-alpha-pyrrolidinopentiophenone C16H22FNO 10/2/20 pyrrolidinovalerophenone 4(17)12(2)11-13/h7-8,11,15H, 3-6,9-10H2,1-2H3 InChI=1S/C21H26N4O3/ N,N-diethyl-2-[2-(4-methoxybenzyl)-5-nitro-1H- c1-4-23(5-2)12-13-24-20-11-8-17(25(26)2 Metonitazene C21H26N4O3 9/15/20 benzimidazol-1-yl]ethanamine -
A Rapid and Sensitive LC–MS/MS Assay for the Quantitation Of
edicine s M & rt D o o p p i S n f g o S Journal of Sports Medicine & Doping Miroshnichenko et al., J Sports Med Doping Stud 2013, 3:1 l t a u n d r i e u DOI: 10.4172/2161-0673.1000120 s o J Studies ISSN: 2161-0673 Research Article Open Access A Rapid and Sensitive LC–MS/MS Assay for the Quantitation of Bromantane in Human Plasma Igor I Miroshnichenko, Svetlana A Sergeeva, Angelina I Platova* and Lyudmila M Krasnykh Mental Health Research Center of RAMS, Moscow, Russia Abstract The purpose of this study was to develop and validate a high-performance liquid chromatographic–tandem mass spectrometric (LC–MS/MS) method for analysis of the bromantane in human plasma. The analyte and Internal Standard (IS), selenox, were extracted from human plasma by solid-phase extraction and separated on a Zorbax SB-C18 column using methanol–0.2% formic acid as mobile phase. Detection was performed using an atmospheric pressure chemical ionization source and mass spectrometric positive Multi-Reaction-Monitoring-Mode (+MRM) at an ion voltage of +2000 V. The assay was linear over the concentration range 1–500 ng/mL with the Lowest Limit of Quantification (LLOQ) of 1 ng/mL. The method also afforded satisfactory results in terms of the sensitivity, specificity, precision (intra- and inter-day, CV<10%), accuracy, recovery as well as the stability of the analyte under various conditions. The method can be applied to pharmacokinetic and toxicological studies. Keywords: Bromantane; Liquid Chromatography–Mass Spectrom- over LLE, including better specificity, the ability to obtain cleaner etry (LC–MS/MS); APCI; Plasma samples, good reproducibility, and a substantial reduction in the volume of solvent required [13]. -
Performance-Enhancing Drugs: a Review G
Performance-Enhancing Drugs: A Review G. Keith Gill, MD Department of Orthopaedics & Rehabilitation, The University of New Mexico Health Sciences Center, Albuquerque, New Mexico Abstract and evaluate the effects of performance-enhancing drugs in sports, I reviewed historical perspectives and current Performance-enhancing drugs and substances have been studies on commonly used anabolic steroids and related an integral part of athletics and society. The immense substances such as androstenedione, human growth popularity and financial compensation associated with hormone (HGH), Beta-2 agonists, stimulants, creatine, success in sports often results in a desire to win at all erythropoietin (EPO), beta blockers, and beta-hydroxy- costs, which stimulates a never-ending appetite for use beta-methylbutyrate (HMB). of ergogenic aids. Athletes have experimented with these substances (ranging from over-the-counter supplements to Development of Performance-Enhancing anabolic-androgenic steroids and beyond) if a possibility Drugs: Modern Era of advantage exists, whether scientifically or theoretically supported. As the technology to create new designer drugs The modern era of performance-enhancing drugs began becomes more available, the ability to test for the presence in 1865 when Dutch swimmers experimented with of these substances lags slightly behind. The knowledge stimulants. Fifteen years later, two competitive cyclists base of sports-medicine physicians must constantly grow died after eating ether-coated sugar cubes and drinking as new drugs -
Illegal Manipulation of Your Body
ES.010 Chemistry of Sports Illegal manipulation of your body Schedule of events for today: 1. Update on workout on Thursday – in the pool 4 pm. 2. Drugs in sports 3. Introduction to Wind tunnel testing – preview of next week’s class with Kim Blair. Drugs in Sports • Blood Doping, Artificial • THG Oxygen Carriers and • Human Chorionic Erythropoietin (EPO) Gonadotrophin (HCG) • Human Growth Hormone • Adrenocorticotropic Hormone • Anabolic Steroids (ACTH) • Insulin-like Growth Factor • Beta-2-Agonists (IGF-1) • Hormone Antagonists and • Cocaine Modulators • Caffeine • Diuretics • Narcotics • Gene Doping • Cannabinoids • Amphetamines Why do Athletes Take Drugs? There are a large number of reasons why an athlete may decide to take drugs. A selection are listed here: • Pressure to succeed, either from themselves or coaches/family and sponsors (major reason) • Belief that their competitors are taking drugs • Pressure from governments/national authorities (as occurred in the eastern bloc countries in the 60's and 70's) • Financial rewards for outstanding performance • Lack of access to, or funding for training facilities and additional support (nutrition, psychological support) • Community and media attitudes and expectations of success Reference:http://www.teachpe.com/drugs/drugs.php. Drugs in Sports • Blood Doping and Erythropoietin • THG (EPO) • Human Chorionic Gonadotrophin • Human Growth Hormone (HCG) • Anabolic Steroids • Adrenocorticotropic Hormone • Insulin-like Growth Factor (IGF- (ACTH) 1) • Beta-2-Agonists • Cocaine • Hormone Antagonists -
Steroids in Baseball and the Case Against Roger Clemens Daniel Healey
Marquette Sports Law Review Volume 19 Article 11 Issue 1 Fall Fall of the Rocket: Steroids in Baseball and the Case Against Roger Clemens Daniel Healey Follow this and additional works at: http://scholarship.law.marquette.edu/sportslaw Part of the Entertainment and Sports Law Commons Repository Citation Daniel Healey, Fall of the Rocket: Steroids in Baseball and the Case Against Roger Clemens , 19 Marq. Sports L. Rev. 289 (2008) Available at: http://scholarship.law.marquette.edu/sportslaw/vol19/iss1/11 This Symposium is brought to you for free and open access by the Journals at Marquette Law Scholarly Commons. For more information, please contact [email protected]. FALL OF THE ROCKET: STEROIDS IN BASEBALL AND THE CASE AGAINST ROGER CLEMENS DANIEL HEALEY* INTRODUCTION - THE ROCKET ON THE HILL Athletes who are chemically propelled to victory do not merely overvalue winning, they misunderstand why winning is properly valued .... Drugs that make sport exotic, by radical intrusions into the body, drain sport of its exemplary power by making it a display of chemistry rather than character. In fact, it becomes a display of some chemists' virtuosity and some athletes' bad character. - George F. Will1 On February 13, 2008, Roger Clemens (Clemens) traveled to Capitol Hill to clear his name. A seven-time Cy Young Award-winning pitcher for the Boston Red Sox, Toronto Blue Jays, New York Yankees, and Houston Astros, "the Rocket" had come to the end of his career, but only the beginning of his legal and media troubles. In December 2007, Clemens's trainer, Brian McNamee (McNamee), had implicated his former employer as a steroids user in the "Mitchell Report," the definitive account of the proliferation of performance-enhancing drugs (PEDs) in Major League Baseball (MLB).2 After facing two months of intense media scrutiny, Clemens traveled to the Hill to testify before the House Committee on Oversight and Government Reform (the "Committee") that he had never used PEDs. -
Nootropics- Memory Boosters
Harikumar K. et al. / Journal of Pharmaceutical Biology, 6(1), 2016, 14-19. Journal of Pharmaceutical Biology www.jpbjournal.com e-ISSN - 2249-7560 Print ISSN - 2249-7579 NOOTROPICS- MEMORY BOOSTERS K.Hari Kumar*, Mitta Srija, D.K.Sandeep, Ramisetty Davarika, Gunda Sai Mounica Department of Pharmacology, Sri Venkateswara College of Pharmacy, R.V.S.Nagar, Chittoor-517127, Andhra Pradesh, India. ABSTRACT Nootropics also called as smart drug, memory enhancers, neuron enhancers, cognitive enhancers and intelligent enhancers are drugs, supplements, neutraceuticals and functional foods that provide one or more aspects of mental function. Specific effect can include improvement to working memory motivation or attention. Nootropics drugs are able to promote, enhance and protect cognitive functions. As cognition is the typically human higher activity of brain, nootropic concept looked quite appealing for scores of people dreaming to enjoy better and longer lasting mental activity and for drug maker keen to produce such enviable products. There are large number of drugs which can be used as nootropic agents and help to enhance memory of people. Nootropics offer lot of benefits for cognitive aptitude and brain health. Nootropics used for the treatment of Alzheimer’s disease, Parkinson’s disease and Huntington’s disease, dementia and cognitive symptoms of schizophrenia. Keywords: Nootropics, Huntington’s disease, Dementia, Alzheimer’s disease. INTRODUCTION It is derived from Greek words “NOOS –Mind” But non-ADHD medications and supplements are more “Tropein – Turn/Bend”. They are also called as memory frequently used for performance enhancement. Many enhancers, Smart nutrients, Cerebroactive drugs and individuals use these drugs for performance enhancement cognition enhancers. -
New Psychoactive Substances (NPS)
New Psychoactive Substances (NPS) LGC Quality Reference ISO 9001 ISO/IEC 17025 ISO Guide 34 materials GMP/GLP ISO 13485 2019 ISO/IEC 17043 Science for a safer world LGC offers the most extensive and up-to-date range of New LGC is a global leader in Psychoactive Substances (NPS) measurement standards, reference materials. reference materials, laboratory services and proficiency testing. With 2,600 professionals working When you make a decision using The challenge The LGC response We are the UK’s in 21 countries, our analytical our resources, you can be sure it’s designated National measurement and quality control based on precise, robust data. And New Psychoactive Substances In response to the ever-expanding LGC Standards provides the widest Measurement services are second-to-none. together, we’re creating fairer, safer, (NPS) continue to be identified, range of NPS being developed, LGC range of reference materials Institute for chemical more confident societies worldwide. and it appears that moves by the has produced a comprehensive available from any single supplier. and bioanalytical As a global leader, we provide the United Nations and by individual range of reference materials that We work closely with leading widest range of reference materials lgcstandards.com countries to control lists of meet the rapidly changing demands manufacturers to provide improved measurement. available from any single supplier. named NPS may be encouraging of the NPS landscape. Many of access to reference materials, the development of yet further these products are produced under with an increasingly large range variants to avoid these controls. the rigorous quality assurance of parameters, for laboratories standards set out in ISO Guide 34. -
Sleep- and Wake-Promoting Drugs: Where Are They Being Sourced, and What Is Their Impact?
Substance Use & Misuse ISSN: 1082-6084 (Print) 1532-2491 (Online) Journal homepage: https://www.tandfonline.com/loi/isum20 Sleep- and Wake-Promoting Drugs: Where Are They Being Sourced, and What Is Their Impact? Rowan P. Ogeil, James G. Phillips, Michael Savic & Daniel I. Lubman To cite this article: Rowan P. Ogeil, James G. Phillips, Michael Savic & Daniel I. Lubman (2019): Sleep- and Wake-Promoting Drugs: Where Are They Being Sourced, and What Is Their Impact?, Substance Use & Misuse, DOI: 10.1080/10826084.2019.1609040 To link to this article: https://doi.org/10.1080/10826084.2019.1609040 Published online: 08 Jul 2019. Submit your article to this journal Article views: 4 View Crossmark data Full Terms & Conditions of access and use can be found at https://www.tandfonline.com/action/journalInformation?journalCode=isum20 SUBSTANCE USE & MISUSE https://doi.org/10.1080/10826084.2019.1609040 ORIGINAL ARTICLE Sleep- and Wake-Promoting Drugs: Where Are They Being Sourced, and What Is Their Impact? Rowan P. Ogeila,b , James G. Phillipsc, Michael Savica,b , and Daniel I. Lubmana,b aEastern Health Clinical School, Monash University, Box Hill, VIC, Australia; bTurning Point, Eastern Health, Richmond, VIC, Australia; cPsychology Department, Auckland University of Technology, Auckland, New Zealand ABSTRACT KEYWORDS Background: Recent decades have seen both an increased number of shift workers in order to deliver Sleep-promoting drug; services 24/7, and increased potential for social interactions at all hours of the day. People have wake-promoting drug; sought to engage in strategies, which either promote vigilance or facilitate sleep, with the use of sleep quality; performance; insomnia; daytime sleep- and wake-promoting drugs representing one strategy.